In 1981, a phase II study confirmed single-agent cisplatin 50 mg/m 2 administered every 3 weeks as the standard therapeutic regimen for patients with cervical cancer. 2 In this trial, the response ...

Another randomized multicenter study was conducted by Seynaeve and collegues [4] and included 535 chemotherapy- naive patients receiving cisplatin, 50-120 mg/m 2. Patients were randomized to ...

A new study from Cedars-Sinai Cancer reveals a potential way to overcome tumor resistance to a common chemotherapy drug called cisplatin ... Nearly 50% of all patients who receive chemotherapy ...